Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $3.58 USD
Change Today +0.13 / 3.77%
Volume 966.8K
IDRA On Other Exchanges
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

idera pharmaceuticals inc (IDRA) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/13/15 - $5.48
52 Week Low
10/10/14 - $1.94
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

idera pharmaceuticals inc (IDRA) Related Businessweek News

No Related Businessweek News Found

idera pharmaceuticals inc (IDRA) Details

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for oncology and rare diseases in the United States. It uses two proprietary drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and gene silencing oligonucleotide (GSO) technology. The company’s lead drug candidate includes IMO-8400, which is in Phase 1/2 clinical trials for the treatment of Waldenström’s Macroglobulinemia, diffuse large B-cell lymphoma, and Duchenne muscular dystrophy, as well as in Phase 2 clinical trial for the treatment of dermatomyositis. Its products also comprise IMO-9200, a drug candidate in Phase 1 clinical trial for use in selected autoimmune disease indications; and IMO-2055/IMO-2125 that are in Phase 1/2 clinical trials for applications as immune therapies for the treatment of cancer. In addition, the company is developing GSOs to turn off the messenger RNA associated with disease causing genes. It has license and research collaboration agreement with Merck & Co. to research, develop, and commercialize vaccine adjuvants containing TLR7, TLR8, and TLR9 agonists in the fields of cancer, infectious diseases, and Alzheimer’s disease; and an agreement with Abbott Molecular Inc. for the development of an in vitro companion diagnostic test. Idera Pharmaceuticals, Inc. was founded in 1989 and is based in Cambridge, Massachusetts.

45 Employees
Last Reported Date: 03/12/15
Founded in 1989

idera pharmaceuticals inc (IDRA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $50.0K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $425.9K
President of Research and Director
Total Annual Compensation: $856.4K
Compensation as of Fiscal Year 2014.

idera pharmaceuticals inc (IDRA) Key Developments

Idera Pharmaceuticals Appoints Mark J. Casey as General Counsel and Secretary of the Board of Directors

Idera Pharmaceuticals, Inc. has appointed Mark J. Casey as Senior Vice President, General Counsel and Secretary of the Board of Directors. Mr. Casey most recently served as Chief Administrative Officer, Senior Vice President, General Counsel and Secretary of Hologic Incorporated.

Idera Pharmaceuticals Enters into Strategic Clinical Research Alliance with The University of Texas MD Anderson Cancer Center to Advance Clinical Development of Intratumoral TLR9 Agonist in Combination with Checkpoint Inhibitors

Idera Pharmaceuticals, Inc. announced that the company has entered into a strategic clinical research alliance with The University of Texas MD Anderson Cancer Center to advance clinical development of intratumoral TLR9 agonist in combination with checkpoint inhibitors. IMO-2125 is a TLR9 agonist which has been evaluated subcutaneously in over 80 human subjects, was well tolerated, and was shown to induce immune responses. The company intends to initiate the first trial of the research alliance, a Phase 1/2 study to assess the safety and efficacy of Intratumoral IMO-2125 in combination with ipilimumab (a CTLA4 antibody) in patients with metastatic melanoma. In this trial, escalating doses of IMO-2125 will be administered intratumorally into a lesion, with a standard dosing regimen of ipilimumab. The primary objectives of the trial will be to determine the maximum tolerated dose (MTD) and characterize the dose-limiting toxicities (DLTs) of IMO-2125 when administered intratumorally in combination with ipilimumab, as well as to determine the efficacy of the combination utilizing the immune-related response criteria (irRC). The company has already filed and received FDA feedback to a Pre-Investigational New Drug Application (PIND) for IMO-2125 and intends to submit an Investigational New Drug application (IND) and initiate the clinical study in the second half of the year 2015. The trial will enroll approximately 45 patients. The company expects data to be available in 2016. The study will be led by Adi Diab, MD, Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, MD Anderson. Additional trials as part of the broader, clinical research alliance are currently in the planning stages.

Idera Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-01-2015 01:30 PM

Idera Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-01-2015 01:30 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Vincent J. Milano, Chief Executive Officer, President and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IDRA:US $3.58 USD +0.13

IDRA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IDRA.
View Industry Companies

Industry Analysis


Industry Average

Valuation IDRA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3,485.4x
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2,810.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IDERA PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at